NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDNivolumab Opdivo®
(10mg/1mL concentrate for solution for infusion) 		Malignant disease and immunosuppression, Other immunomodulating drugs, 08.02.04
REDNivolumab / Relatlimab Opdualag®
(240 mg/80 mg concentrate for solution for infusion) 		Malignant disease and immunosuppression, Other immunomodulating drugs, 08.02.04
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Nivolumab  Nivolumab [Specialist Drug] Malignant Disease, Antineoplastic Drugs, Monoclonal Antibodies
Antibody Responsive Malignancy
Nivolumab  Nivolumab With Relatlimab [Specialist Drug] Malignant Disease, Antineoplastic Drugs, Monoclonal Antibodies
Antibody Responsive Malignancy
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
MHRA Drug Safety Update (July 2017) -Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
MHRA Drug Safety Update (October 2019): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
NICE TA1065: Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
NICE TA1127: Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
NICE TA462:Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
NICE TA490:Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
NICE TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
NICE TA713 Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
NICE TA724 Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer
NICE TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer
NICE TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
NICE TA746: Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer
NICE TA780 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
NICE TA817: Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence
NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
NICE TA857: Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
NICE TA865: Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
NICE TA876: Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
NICE TA964: Cabozantinib with nivolumab for untreated advanced renal cell carcinoma
NICE TA980: Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (TERMINATED APPRAISAL)